ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
ETx-22, a novel ADC combining a tumor nectin-4-specific antibody and an innovative linker to exatecan, demonstrates significant and durable responses in low-target-expressing tumor models that are resistant to MMAE-based EV and has a better toxicity profile. This new ADC has the potential to benefit additional patient populations beyond its current indication.
Authors
- Anne Farina (ORCID: https://orcid.org/0000-0002-6693-8590)
- François Romagné
- Jack Elands
- Emmanuelle Charafe‐Jauffret (ORCID: https://orcid.org/0000-0002-0286-1299)
- Stéphanie Blanchin
- Rémy Castellano (ORCID: https://orcid.org/0000-0002-0152-985X)
- Florence Lhospice (ORCID: https://orcid.org/0000-0002-2868-1181)
- Torsten Hechler (ORCID: https://orcid.org/0000-0002-1000-8407)
- Anikó Pálfí
- Daniel Olive (ORCID: https://orcid.org/0000-0003-1299-4113)
- Hatem A. Azim (ORCID: https://orcid.org/0000-0003-4865-3193)
- Maria Wehbe (ORCID: https://orcid.org/0000-0003-2900-2811)
- Émilie Mamessier (ORCID: https://orcid.org/0000-0002-3516-0093)
- Joanna Fares
- Andreas Pahl (ORCID: https://orcid.org/0000-0002-6294-0335)
- Yves Collette (ORCID: https://orcid.org/0000-0001-5359-7099)
- Marc Lopez (ORCID: https://orcid.org/0000-0002-6573-633X)
- Emerence Crompot (ORCID: https://orcid.org/0000-0002-2761-6126)
- Xavier Préville (ORCID: https://orcid.org/0000-0002-1416-7405)
- Marion Rubis
- Emmanuelle Josselin (ORCID: https://orcid.org/0000-0002-7647-9949)
- François Bertucci (ORCID: https://orcid.org/0000-0002-0157-0959)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Eli Lilly (United States) (US)
- Aix-Marseille Université (FR)
- Centre Norbert Elias (FR)
- Heidelberg Pharma (Germany) (DE)
- Délégation Provence et Corse (FR)
- Centre de Recherche en Cancérologie de Marseille (FR)
- Institut Paoli-Calmettes (FR)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2024-10-23
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0176
- Citations
- 6
- Primary Topic
- Galectins and Cancer Biology
- Type
- article
- Field-Weighted Citation Impact
- 1.44
Funders
- Institut National de la Santé et de la Recherche Médicale
- Ligue Contre le Cancer
- Société d'Accélération du Transfert de Technologies